# US 8,784,887 B2 · Pharmaceutical preparation of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,784,887 B2 - Document ID: US8784887B2 - Status: Granted - Kind: B2 - Application number: 11/904,712 - Filed: 2007-09-27 - Published: 2008-09-11 - Granted: 2014-07-22 - Earliest claimed: 2005-03-30 - Assignees: AiCuris GmbH & Co. KG - Applicants: Tobias Laich; Katrin Liebelt - Inventors: Tobias Laich; Katrin Liebelt - Web page: https://patentgrep.com/patent/US8784887B2 ## CPC - A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose} - A61K 9/2013: {Organic compounds, e.g. phospholipids, fats} - A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose} - A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63) - A61K 31/426: 1,3-Thiazoles - A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) - A61P 31/22: for herpes viruses - C07D 417/12: linked by a chain containing hetero atoms as chain links - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) ## Abstract The invention relates to a pharmaceutical preparation for oral administration comprising N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide or its hydrates and/or solvates, as well as an acid, a method for its production as well as the use of this preparation for the treatment and/or prophylaxis of diseases which are caused by herpes viruses, in particular diseases which are caused by herpes simplex viruses. ## Claims ### Claim 1 A pharmaceutical preparation for oral application comprising N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide or a hydrate thereof, optionally one or more dry binders, at least one disintegration auxiliary, at least one lubricant and optionally a tenside, said preparation comprising methanesulfonic acid which is used in a stoichiometric ratio of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide or said hydrate to acid of 1 to 0.10 to 1.10 whereby said acetamide and said acid form a salt. ### Claim 2 (depends on 1) The preparation of claim 1, comprising 30 to 1200 mg of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide or a hydrate based on a single tablet. ### Claim 3 (depends on 1) The preparation of claim 1, wherein said dry binder is microcrystalline cellulose. ### Claim 4 (depends on 1) The preparation of claim 1, wherein said disintegration auxiliary is croscarmellose sodium or a mixture of croscarmellose sodium and cross-linked polyvinylpyrrolidone (4:1). ### Claim 5 (depends on 1) The preparation of claim 1, wherein said lubricant is magnesium stearate. ### Claim 6 (depends on 1) The preparation of claim 1, wherein said tenside is polysorbate 80. ### Claim 7 (depends on 1) The preparation of claim 1, comprising: 50 to 70% N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide or hydrates thereof, 15 to 29% croscarmellose sodium and cross-linked polyvinylpyrrolidone (4:1), 0.5 to 1.1% magnesium stearate, 1 to 5% microcrystalline cellulose, optionally 0.4 to 0.5% polysorbate 80, as well as methanesulfonic acid with a stoichiometric ratio of acetamide to acid of 1 to 0.90 to 0.98 whereby said acetamide and said acid form a salt. ### Claim 8 (depends on 1) A tablet preparation for oral application comprising a core of said pharmaceutical preparation of claim 1 and a varnish coating. ### Claim 9 (depends on 1) The preparation of claim 1, comprising N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide. ### Claim 10 (depends on 8) The preparation of claim 8, comprising N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide. ### Claim 11 (depends on 1) The preparation of claim 1 for the treatment of diseases which are caused by herpes viruses, in particularly diseases which are caused by herpes simplex viruses. ### Claim 12 (depends on 8) The preparation of claim 8 for the treatment of diseases which are caused by herpes viruses, in particularly diseases which are caused by herpes simplex viruses. ### Claim 13 (depends on 1) A method for the production of the pharmaceutical preparation for oral application of claim 1, wherein N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide or a hydrate thereof, optionally one or more dry binders and an acid are subjected to an aqueous granulation to form granules, said granules are subsequently mixed with at least one disintegration auxiliary and at least one lubricant and optionally a wetting agent and optionally tabletted and varnished. ### Claim 14 (depends on 8) A method for the production of the pharmaceutical preparation for oral application of claim 8, wherein N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide or a hydrate thereof, optionally one or more dry binders and an acid are subjected to an aqueous granulation to form granules, said granules are subsequently mixed with at least one disintegration auxiliary and at least one lubricant and optionally a wetting agent and optionally tabletted and varnished. ### Claim 15 A compound selected from the group consisting of: N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate, and its hydrates. ### Claim 16 (depends on 1) The preparation of claim 1, wherein, when treated with 0.1 N HCl at 37° C., the preparation releases said acetamide faster than a preparation lacking methanesulfonic acid releases said acetamide. ### Claim 17 (depends on 1) The preparation of claim 1, wherein at least 80% of said acetamide is released from the preparation within 30 minutes in 0.1 N HCl at 37° C.